Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-21-053318
Filing Date
2021-10-18
Accepted
2021-10-18 17:18:08
Documents
10
Period of Report
2021-11-09

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT ea148950-def14a_actinium.htm DEF 14A 681388
2 GRAPHIC image_001.jpg GRAPHIC 4265
3 GRAPHIC image_002.jpg GRAPHIC 8475
4 GRAPHIC image_003.jpg GRAPHIC 13917
5 GRAPHIC image_004.jpg GRAPHIC 23220
6 GRAPHIC image_005.jpg GRAPHIC 24383
7 GRAPHIC image_006.jpg GRAPHIC 14660
8 GRAPHIC image_007.jpg GRAPHIC 734
9 GRAPHIC proxy_001.jpg GRAPHIC 123991
10 GRAPHIC proxy_002.jpg GRAPHIC 175810
  Complete submission text file 0001213900-21-053318.txt   1220030
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36374 | Film No.: 211328911
SIC: 2834 Pharmaceutical Preparations